Limits...
Impact of interleukin-6 promoter polymorphism and serum interleukin-6 level on the acute inflammation and neovascularization stages of patients with Eales' disease.

Sen A, Paine SK, Chowdhury IH, Mukherjee A, Choudhuri S, Saha A, Mandal LK, Bhattacharya B - Mol. Vis. (2011)

Bottom Line: Serum IL-6 also significantly correlated with hsCRP (Spearman's correlation coefficient; r=0.4992, p=0.0009), but not with VEGF in this stage in ED patients.A statistically significant association was found between the -174GG genotype (p=0.006) and occurrence of ED.IL-6 expression, regulated by the allelic distribution of -174 loci and the enhanced level of IL-6, modulates CRP and VEGF concentration depending respectively on the acute inflammatory stimulation at the initial stage and angiogenic stimulation at the advanced stage of ED.

View Article: PubMed Central - PubMed

Affiliation: Department of Biochemistry, Dr. B C Roy Post Graduate Institute of Basic Medical Education and Research (IPGME&R), Kolkata, India.

ABSTRACT

Purpose: To evaluate the role of interleukin-6 (IL-6) in the inflammatory and proliferative stages of Eales' disease (ED) and to determine the influence of IL-6-174G/C polymorphism in the IL-6 and IL-6-regulated protein expression, as well as the development of ED.

Methods: One hundred and twenty-one patients diagnosed with ED, 223 matched healthy controls, and 16 control patients with macular holes were recruited from the eastern Indian population. Serum and vitreous levels of IL-6 and vascular endothelial growth factors (VEGF) were measured by enzyme-linked immunosorbent assay. Serum levels of high-sensitivity C-reactive protein (hsCRP) were measured by enzyme immunoassay. Subjects were genotyped for the IL-6-174G/C polymorphism (rs1800795) by a custom TaqMan single-nucleotide polymorphism (SNP) Genotyping Assays system.

Results: Serum IL-6 (p<0.0001), hsCRP (p<0.0001), and VEGF (p=0.0031) levels were significantly higher in the inflammatory stage of ED than in healthy controls. Serum IL-6 also significantly correlated with hsCRP (Spearman's correlation coefficient; r=0.4992, p=0.0009), but not with VEGF in this stage in ED patients. At the proliferative stage of ED, significantly higher levels of vitreous IL-6 (p=<0.0001) and VEGF (p=<0.0001) were found compared with the vitreous of patients with macular holes. A significant correlation was observed between vitreous IL-6 and VEGF in ED patients (Spearman's correlation coefficient; r=0.5834, p=0.0087). A statistically significant association was found between the -174GG genotype (p=0.006) and occurrence of ED. Mean serum and vitreous concentrations of IL-6 were also higher in the subjects with the GG genotype than in those with the GC or CC genotype in this population.

Conclusions: IL-6 expression, regulated by the allelic distribution of -174 loci and the enhanced level of IL-6, modulates CRP and VEGF concentration depending respectively on the acute inflammatory stimulation at the initial stage and angiogenic stimulation at the advanced stage of ED.

Show MeSH

Related in: MedlinePlus

Vitreous protein concentration in study subjects according to −174G/C genotype. Vitreous concentrations of: A: interleukin-6 (IL-6) and B: vascular endothelial growth factor (VEGF) in patients with Eales’ disease (ED) at the proliferative stage and control patients for each −174G/C genotype. The Mann–Whitney U test was performed to determine whether significant differences were present within the same groups of subjects with different −174G/C genotypes. The results of this analysis are indicated in brackets. An asterisk denotes a significant p value.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3198485&req=5

f4: Vitreous protein concentration in study subjects according to −174G/C genotype. Vitreous concentrations of: A: interleukin-6 (IL-6) and B: vascular endothelial growth factor (VEGF) in patients with Eales’ disease (ED) at the proliferative stage and control patients for each −174G/C genotype. The Mann–Whitney U test was performed to determine whether significant differences were present within the same groups of subjects with different −174G/C genotypes. The results of this analysis are indicated in brackets. An asterisk denotes a significant p value.

Mentions: In the proliferative stage of ED, vitreous concentrations of IL-6 and VEGF were significantly higher in patients with the GG genotype than the GC genotype (101.5 pg/ml versus 42.58 pg/ml; p=0.0015 and 1151.0 pg/ml versus 899.0 pg/ml; p=0.0067). We found no patients with the CC genotype in this stage. Vitreous IL-6 concentration also showed a similar trend in the case of control patients with macular holes. However, vitreous VEGF concentration in control patients did not show any significant variation with IL-6–174G/C polymorphism (Figure 4) Mean vitreous concentrations of IL-6 and VEGF were significantly higher in patients in the proliferative stage than control patients with macular holes for all IL-6-174G/C genotypes (Table 7).


Impact of interleukin-6 promoter polymorphism and serum interleukin-6 level on the acute inflammation and neovascularization stages of patients with Eales' disease.

Sen A, Paine SK, Chowdhury IH, Mukherjee A, Choudhuri S, Saha A, Mandal LK, Bhattacharya B - Mol. Vis. (2011)

Vitreous protein concentration in study subjects according to −174G/C genotype. Vitreous concentrations of: A: interleukin-6 (IL-6) and B: vascular endothelial growth factor (VEGF) in patients with Eales’ disease (ED) at the proliferative stage and control patients for each −174G/C genotype. The Mann–Whitney U test was performed to determine whether significant differences were present within the same groups of subjects with different −174G/C genotypes. The results of this analysis are indicated in brackets. An asterisk denotes a significant p value.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3198485&req=5

f4: Vitreous protein concentration in study subjects according to −174G/C genotype. Vitreous concentrations of: A: interleukin-6 (IL-6) and B: vascular endothelial growth factor (VEGF) in patients with Eales’ disease (ED) at the proliferative stage and control patients for each −174G/C genotype. The Mann–Whitney U test was performed to determine whether significant differences were present within the same groups of subjects with different −174G/C genotypes. The results of this analysis are indicated in brackets. An asterisk denotes a significant p value.
Mentions: In the proliferative stage of ED, vitreous concentrations of IL-6 and VEGF were significantly higher in patients with the GG genotype than the GC genotype (101.5 pg/ml versus 42.58 pg/ml; p=0.0015 and 1151.0 pg/ml versus 899.0 pg/ml; p=0.0067). We found no patients with the CC genotype in this stage. Vitreous IL-6 concentration also showed a similar trend in the case of control patients with macular holes. However, vitreous VEGF concentration in control patients did not show any significant variation with IL-6–174G/C polymorphism (Figure 4) Mean vitreous concentrations of IL-6 and VEGF were significantly higher in patients in the proliferative stage than control patients with macular holes for all IL-6-174G/C genotypes (Table 7).

Bottom Line: Serum IL-6 also significantly correlated with hsCRP (Spearman's correlation coefficient; r=0.4992, p=0.0009), but not with VEGF in this stage in ED patients.A statistically significant association was found between the -174GG genotype (p=0.006) and occurrence of ED.IL-6 expression, regulated by the allelic distribution of -174 loci and the enhanced level of IL-6, modulates CRP and VEGF concentration depending respectively on the acute inflammatory stimulation at the initial stage and angiogenic stimulation at the advanced stage of ED.

View Article: PubMed Central - PubMed

Affiliation: Department of Biochemistry, Dr. B C Roy Post Graduate Institute of Basic Medical Education and Research (IPGME&R), Kolkata, India.

ABSTRACT

Purpose: To evaluate the role of interleukin-6 (IL-6) in the inflammatory and proliferative stages of Eales' disease (ED) and to determine the influence of IL-6-174G/C polymorphism in the IL-6 and IL-6-regulated protein expression, as well as the development of ED.

Methods: One hundred and twenty-one patients diagnosed with ED, 223 matched healthy controls, and 16 control patients with macular holes were recruited from the eastern Indian population. Serum and vitreous levels of IL-6 and vascular endothelial growth factors (VEGF) were measured by enzyme-linked immunosorbent assay. Serum levels of high-sensitivity C-reactive protein (hsCRP) were measured by enzyme immunoassay. Subjects were genotyped for the IL-6-174G/C polymorphism (rs1800795) by a custom TaqMan single-nucleotide polymorphism (SNP) Genotyping Assays system.

Results: Serum IL-6 (p<0.0001), hsCRP (p<0.0001), and VEGF (p=0.0031) levels were significantly higher in the inflammatory stage of ED than in healthy controls. Serum IL-6 also significantly correlated with hsCRP (Spearman's correlation coefficient; r=0.4992, p=0.0009), but not with VEGF in this stage in ED patients. At the proliferative stage of ED, significantly higher levels of vitreous IL-6 (p=<0.0001) and VEGF (p=<0.0001) were found compared with the vitreous of patients with macular holes. A significant correlation was observed between vitreous IL-6 and VEGF in ED patients (Spearman's correlation coefficient; r=0.5834, p=0.0087). A statistically significant association was found between the -174GG genotype (p=0.006) and occurrence of ED. Mean serum and vitreous concentrations of IL-6 were also higher in the subjects with the GG genotype than in those with the GC or CC genotype in this population.

Conclusions: IL-6 expression, regulated by the allelic distribution of -174 loci and the enhanced level of IL-6, modulates CRP and VEGF concentration depending respectively on the acute inflammatory stimulation at the initial stage and angiogenic stimulation at the advanced stage of ED.

Show MeSH
Related in: MedlinePlus